Clinical Trial

To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the safety of the drug in these patients after a single dose.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-07
Trial Details
NCT Number NCT07480824
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Myelofibrosis
Enrollment 24 participants
Start Date 2026-04-01
Primary Completion 2026-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06